Company Analysis
Sign in

MeiraGTx Holdings plc (MGTX)

Nasdaq: MGTX · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2018
Full chart Alerts Compare
Grade6.2
◀ Past 7.1● Present 5.9▶ Future 5.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$81.4M+144.6%
Net income-$114M+22.7%
Earnings per share$-1.42+33.0%
Operating cash flow-$46.4M+55.6%
Cash$68.2M-35.5%
Debtn/a
Shareholders’ equity-$5.8M-108.5%
Shares, diluted80.4M+15.2%
Return on equityn/a
The recordfrom its filings
Filings in 202682
Newest filingNov 12 · S-3ASR
Annual reportMar 30, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$4.9M
Insider buys, 12 months$0.00
Patents granted9
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $402MNet income $78.3MCash from operations $1.4Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form S-3ASR
Shelf registration
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 6, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 24, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 23, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton MGTX · research, not advice